Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Novel Approaches Gain Ground in Diffuse Large B-Cell Lymphoma

February 28th 2020

Despite advances made in the treatment of patients with diffuse large B-cell lymphoma, investigators are on a quest to move more novel agents through the pipeline, says Craig Moskowitz, MD, in a presentation during the 24th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma.

Gemtuzumab Ozogamicin Misses Early EFS Endpoint, as Phase III Study Continues in NPM1+ AML

February 26th 2020

Gemtuzumab ozogamicin in combination with intensive induction therapy was associated with a higher early death rate compared with induction therapy alone in patients with NPM1-mutated acute myeloid leukemia.

Dr. Daver on Azacitidine and Nivolumab in Acute Myeloid Leukemia

February 26th 2020

Naval G. Daver, MD, discusses the rationale of azacitidine and nivolumab in acute myeloid leukemia.

Dr. Blum on the Current Treatment Landscape of Acute Myeloid Leukemia

February 26th 2020

William G. Blum, MD, discusses the current treatment landscape of acute myeloid leukemia.

Optimal Treatment Selection Needed in Advanced Follicular Lymphoma

February 26th 2020

Benjamin Heyman, MD, discusses frontline and maintenance therapy options, novel targeted approaches, and the expanding role of minimal residual disease in patients with follicular lymphoma.

Long-Term Data Spark Investigation of Brentuximab Combos in Hodgkin Lymphoma Subgroups

February 25th 2020

Ayad Hamdan, MD, discusses the impact of the 4-year follow-up data from the ECHELON-1 trial in advanced-stage Hodgkin lymphoma.

Dr. Vusirikala on Hyper-CVAD Plus Ponatinib in Philadelphia Chromosome-Positive ALL

February 25th 2020

Madhuri Vusirikala, MD, discusses the benefit of hyper-CVAD and ponatinib in patients with Philadelphia chromosome–positive ALL.

Standard Myeloma Therapies Transform to Triplet, Quadruplet Regimens

February 25th 2020

Caitlin Costello, MD, discusses pivotal research in the relapsed/refractory multiple myeloma setting.

KD025 Induces Impressive Activity in cGVHD

February 25th 2020

The selective ROCK2 inhibitor KD025 induced clinical responses in approximately two-thirds of patients with chronic graft-versus-host disease, including complete responses in 3 patients.

CAR-T Leads Advances Across Lymphomas, But Further Research Needed

February 25th 2020

Dimitrios Tzachanis, MD, PhD, discusses updates and remaining questions with CAR T-cell therapy.

Novel Approaches Under Exploration Across Lymphoma Subtypes

February 24th 2020

Erin Reid, MD, discusses the treatment advances across lymphomas and the remaining questions that need to be answered with further research.

Pasireotide Does Not Decrease Risk of GI Toxicity or Acute GVHD Following HSCT

February 24th 2020

Anthony D. Sung, MD, discusses the findings from the phase II trial of pasireotide as a method to prevent gastrointestinal toxicity and acute graft-versus-host-disease in patients who undergo allogeneic hematopoietic stem cell transplant.

Narsoplimab Emerging as Treatment Option for TA-TMA

February 23rd 2020

Narsoplimab (OMS721) is advancing through the therapy pipeline as a novel treatment option for patients with transplant-associated thrombotic microangiopathy.

"Off-the-Shelf" CAR T-Cell Therapy Shows Promise in Non-Hodgkin Lymphoma

February 22nd 2020

An “off-the-shelf” Epstein Barr-virus–specific cytotoxic lymphocyte CAR product derived from cells harvested from third-party donors induced a 100% response rate in adult and pediatric patients with relapsed/refractory non-Hodgkin lymphoma.

Expert Highlights Remaining Diagnostic Challenges With TA-TMA

February 22nd 2020

Sergio A. Giralt, MD, discusses the diagnostic challenges of transplant-associated thrombotic microangiopathy.

Conditioning Therapy With Iomab-B Leads to High Transplant Rate in Active AML

February 21st 2020

Iodine (131I) apamistamab (Iomab-B) conditioning induced a complete remission in 84% (31/38) of patients with active acute myeloid leukemia, who were then able to receive allogeneic hematopoietic stem cell transplant, according to preliminary results from the phase III SIERRA trial.

Targeted Approaches Under Exploration in Peripheral T-Cell Lymphoma

February 21st 2020

Aaron Goodman, MD, discusses recent changes to the frontline treatment of patients with peripheral T-cell lymphoma and the challenges of targeting T-cell lymphoma.

Dr. Tan on the Risk of Novel Coronavirus for Patients With Cancer

February 21st 2020

Christina Tan, MD, MPH, discusses the potential impact of the novel coronavirus on patients with cancer.

Dr. Heyman on Frontline Treatment Options in Follicular Lymphoma

February 21st 2020

Benjamin Heyman, MD, discusses frontline treatment options for patients with follicular lymphoma.

Ruxolitinib Efficacy in Chronic GVHD Highlighted Across Age Groups

February 21st 2020

Ruxolitinib is an effective and well-tolerated treatment in the refractory setting for patients with chronic graft-versus-host disease, regardless of age.